Radient Reveals New Divestiture Plan for China Subsidiary

Radient Pharmaceuticals announced a new plan to sell its China subsidiary, Jade Pharmaceuticals Inc. Jade has signed a letter of intent to merge with Shanxi BaoTai Pharmaceutical Co., a privately owned company located in Taiyuan China. When the transaction is closed, Jade plans to merge the combined entity with an unnamed public company, and the public company will move its listing to the NYSE Amex. More details.... Stock Symbol: (AMEX: RPC)